Revvity (RVTY) Income from Discontinued Operations (2009 - 2026)
Revvity's (RVTY) quarterly Income from Discontinued Operations came in at -$1.7 million in Q3 2026, down 30.38% on a YoY basis from -$2.4 million in Q3 2025, and down 849.14% quarter-over-quarter from -$175000.0 in Q2 2026.
Analysis
Revvity (RVTY) Income from Discontinued Operations (2009 - 2026) Analysis & Trends
Revvity (RVTY) has reported Income from Discontinued Operations for 18 consecutive years, with -$1.7 million the latest figure, recorded in Q3 2026.
- For the quarter ending Q3 2026, Income from Discontinued Operations fell 30.38% year-over-year to -$1.7 million; the trailing twelve-month figure through Jul 2026 stood at $188000.0 (down 97.12% YoY), and the FY2025 full-year result was $1.3 million, up 110.39% from the prior year.
- Income from Discontinued Operations eased to -$1.7 million in Q3 2026 per RVTY's latest filing, from -$175000.0 in the prior quarter.
- Across five years, Income from Discontinued Operations topped out at $544.6 million in Q2 2023 and bottomed at -$23.1 million in Q3 2023.
- Historically, Income from Discontinued Operations has averaged $30.4 million across 5 years, with a median of $196500.0 in 2025.
- The sharpest annual moves came in 2022 and 2023: Income from Discontinued Operations soared 8449.32% in 2022, then slumped 245.03% in 2023.
- Over 5 years, Income from Discontinued Operations stood at $15.8 million in 2022, then plunged by 245.03% to -$23.0 million in 2023, then soared by 127.26% to $6.3 million in 2024, then sank by 58.59% to $2.6 million in 2025, then plunged by 164.06% to -$1.7 million in 2026.
- According to Business Quant data, Income from Discontinued Operations over the past three periods registered -$1.7 million, -$175000.0, and $2.6 million for Q3 2026, Q2 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 241.68 Bn | 237.61 Bn | 8.34 Bn | - |
| 2 | Danaher | 147.34 Bn | 142.99 Bn | 3.61 Bn | - |
| 3 | Agilent Technologies | 43.34 Bn | 41.59 Bn | 1.04 Bn | - |
| 4 | Illumina | 34.58 Bn | 33.41 Bn | 770.00 Mn | - |
| 5 | Revvity | 16.31 Bn | 15.29 Bn | 416.87 Mn | -1.66 Mn |
| 6 | Bio-Techne | 11.28 Bn | 11.01 Bn | 211.39 Mn | - |
| 7 | Bio-Rad Laboratories | 10.16 Bn | 8.54 Bn | 345.80 Mn | - |
| 8 | Repligen | 9.77 Bn | 8.75 Bn | 110.04 Mn | - |
| 9 | 10x Genomics | 9.45 Bn | 8.90 Bn | 112.50 Mn | - |
| 10 | Bruker | 9.26 Bn | 9.04 Bn | 416.00 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 5, 2026 | -1.66 Mn |
| Apr 5, 2026 | -175,000.00 |
| Dec 28, 2025 | 2.59 Mn |
| Sep 28, 2025 | -569,000.00 |
| Jun 29, 2025 | -1.27 Mn |
| Mar 30, 2025 | 568,000.00 |
| Dec 29, 2024 | 6.26 Mn |
| Sep 29, 2024 | 981,000.00 |
| Jun 30, 2024 | -17.25 Mn |
| Mar 31, 2024 | -2.68 Mn |
| Oct 1, 2023 | -22.97 Mn |
| Jul 2, 2023 | -23.06 Mn |
| Apr 2, 2023 | 544.63 Mn |
| Jan 1, 2023 | 30.16 Mn |
| Oct 2, 2022 | 15.84 Mn |
| Jul 3, 2022 | 17.61 Mn |
| Apr 3, 2022 | -7.11 Mn |
| Jan 2, 2022 | 6.10 Mn |
| Oct 3, 2021 | 20.11 Mn |
| Jul 4, 2021 | 18.07 Mn |